Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

An invertebrate model to evaluate virulence in Aspergillus fumigatus: the role of azole resistance.

Gomez-Lopez A, Forastiero A, Cendejas-Bueno E, Gregson L, Mellado E, Howard SJ, Livermore JL, Hope WW, Cuenca-Estrella M.

Med Mycol. 2014 Apr;52(3):311-9. doi: 10.1093/mmy/myt022. Epub 2014 Feb 4.

PMID:
24577012
2.

Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.

Livermore J, Howard SJ, Sharp AD, Goodwin J, Gregson L, Felton T, Schwartz JA, Walker C, Moser B, Müller W, Harrison TS, Perfect JR, Hope WW.

MBio. 2014 Jan 28;5(1):e00725-13. doi: 10.1128/mBio.00725-13.

3.

In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.

Gregson L, Goodwin J, Johnson A, McEntee L, Moore CB, Richardson M, Hope WW, Howard SJ.

Antimicrob Agents Chemother. 2013 Nov;57(11):5778-80. doi: 10.1128/AAC.01141-13. Epub 2013 Sep 16.

4.

Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.

Felton TW, Goodwin J, O'Connor L, Sharp A, Gregson L, Livermore J, Howard SJ, Neely MN, Hope WW.

Antimicrob Agents Chemother. 2013 Dec;57(12):5811-9. doi: 10.1128/AAC.00867-13. Epub 2013 Sep 3.

5.

Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.

O'Connor L, Livermore J, Sharp AD, Goodwin J, Gregson L, Howard SJ, Felton TW, Schwartz JA, Neely MN, Harrison TS, Perfect JR, Hope WW.

J Infect Dis. 2013 Jul 15;208(2):351-61. doi: 10.1093/infdis/jit164. Epub 2013 Apr 18.

6.

Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.

Sudan A, Livermore J, Howard SJ, Al-Nakeeb Z, Sharp A, Goodwin J, Gregson L, Warn PA, Felton TW, Perfect JR, Harrison TS, Hope WW.

Antimicrob Agents Chemother. 2013 Jun;57(6):2793-800. doi: 10.1128/AAC.00216-13. Epub 2013 Apr 9.

7.

Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis.

Howard SJ, Pasqualotto AC, Anderson MJ, Leatherbarrow H, Albarrag AM, Harrison E, Gregson L, Bowyer P, Denning DW.

Mycoses. 2013 Jul;56(4):434-41. doi: 10.1111/myc.12047. Epub 2013 Feb 1.

PMID:
23369025
8.

Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.

Livermore JL, Felton TW, Abbott J, Sharp A, Goodwin J, Gregson L, Warn PA, Howard SJ, Hope WW.

Antimicrob Agents Chemother. 2013 Jan;57(1):281-8. doi: 10.1128/AAC.01387-12. Epub 2012 Oct 31.

9.

Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.

Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Warn PA, Hope WW.

Antimicrob Agents Chemother. 2012 Oct;56(10):5180-5. doi: 10.1128/AAC.01111-12. Epub 2012 Jul 23.

10.

Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.

Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Majithiya JB, Lass-Flörl C, Cuenca-Estrella M, Arendrup MC, Warn PA, Hope WW.

J Infect Dis. 2012 Aug 1;206(3):442-52. doi: 10.1093/infdis/jis372. Epub 2012 May 25.

PMID:
22634880
11.

Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.

Al-Nakeeb Z, Sudan A, Jeans AR, Gregson L, Goodwin J, Warn PA, Felton TW, Howard SJ, Hope WW.

Antimicrob Agents Chemother. 2012 Aug;56(8):4146-53. doi: 10.1128/AAC.00141-12. Epub 2012 May 21.

12.

In vitro model of invasive pulmonary aspergillosis in the human alveolus.

Gregson L, Hope WW, Howard SJ.

Methods Mol Biol. 2012;845:361-7. doi: 10.1007/978-1-61779-539-8_24.

PMID:
22328387
13.

Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.

Warn PA, Livermore J, Howard S, Felton TW, Sharp A, Gregson L, Goodwin J, Petraitiene R, Petraitis V, Cohen-Wolkowiez M, Walsh TJ, Benjamin DK Jr, Hope WW.

Antimicrob Agents Chemother. 2012 Feb;56(2):708-14. doi: 10.1128/AAC.05826-11. Epub 2011 Nov 28.

14.

Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.

Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A, Perlin DS, Warn PA, Hope WW.

Antimicrob Agents Chemother. 2011 Oct;55(10):4880-7. doi: 10.1128/AAC.00621-11. Epub 2011 Aug 1.

15.

Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.

Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, Alastruey-Izquierdo A, Arendrup MC, Warn PA, Perlin DS, Hope WW.

Antimicrob Agents Chemother. 2011 Jul;55(7):3075-83. doi: 10.1128/AAC.01686-10. Epub 2011 Apr 18.

16.

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.

Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW.

J Infect Dis. 2011 May 1;203(9):1324-32. doi: 10.1093/infdis/jir023. Epub 2011 Feb 28.

17.

Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice.

Slater JL, Gregson L, Denning DW, Warn PA.

Med Mycol. 2011 Apr;49 Suppl 1:S107-13. doi: 10.3109/13693786.2010.523852. Epub 2010 Oct 18.

PMID:
20950221
18.

Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.

Lestner JM, Howard SJ, Goodwin J, Gregson L, Majithiya J, Walsh TJ, Jensen GM, Hope WW.

Antimicrob Agents Chemother. 2010 Aug;54(8):3432-41. doi: 10.1128/AAC.01586-09. Epub 2010 May 3.

Supplemental Content

Loading ...
Support Center